Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines

Martin Michaelis[a], Yvonne Voges[b], Florian Rothweiler[b], Fabian Weipert[c], Amara Zia-Ahmad[b], Jaroslav Cinatl[b], Andreas von Deimling[d], Frank Westermann[e], Franz Rödel[c], Mark N. Wass[a], Jindrich Cinatl jr.[b]*

[a] Industrial Biotechnology Centre and School of Biosciences, University of Kent, Canterbury, UK

[b] Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany

[c] Department of Radiotherapy and Oncology, Goethe-Universität, Frankfurt am Main, Germany

[d] Department of Neuropathology, Ruprecht-Karls-University Heidelberg and Deutsches Krebsforschungszentrum, Heidelberg, Germany

[e] Division Neuroblastoma Genomics, B087, German Cancer Research Center and Hopp Children´s Cancer Center at the NCT (KiTZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

*Corresponding author: e-mail Cinatl@em.uni-frankfurt.de; phone +49 69 6301 6409; fax +49 69 6301 4302

1

Abstract

The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). 77 cell lines displayed YM155 IC_{50}s in the range of clinical YM155 concentrations. ABCB1 was an important determinant of YM155 resistance. The activity of the ABCB1 inhibitor zosuquidar ranged from being similar to that of the structurally different ABCB1 inhibitor verapamil to being 65-fold higher. ABCB1 sequence variations may be responsible for this, suggesting that the design of variant-specific ABCB1 inhibitors may be possible. Further, we showed that ABCC1 confers YM155 resistance. Previously, p53 depletion had resulted in decreased YM155 sensitivity. However, *TP53*-mutant cells were not generally less sensitive to YM155 than *TP53* wild-type cells in this study. Finally, YM155 cross-resistance profiles differed between cells adapted to drugs as similar as cisplatin and carboplatin. In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. Novel findings include that ABCC1 mediates YM155 resistance and that YM155 cross-resistance profiles differ between cell lines adapted to drugs as similar as cisplatin and carboplatin.

Key words: YM155, survivin, neuroblastoma, drug resistance, ABCB1, ABCC1

Introduction

Survivin is a potential drug target in cancer entities including neuroblastoma [1-7], the most frequent solid extracranial paediatric cancer. About half of the patients are diagnosed with high-risk disease associated with overall survival rates below 50% despite myeloablative therapy and differentiation therapy using retinoids. While many neuroblastomas respond initially well to therapy, acquired drug resistance represents a major clinical problem [8,9].

YM155 (sepantronium bromide) was introduced as a suppressor of survivin expression that displayed anti-cancer activity in pre-clinical models of different cancer entities including neuroblastoma [3-5,7,10]. However, DNA damage induction and Mcl-1 depletion were later suggested as additional or alternative anti-cancer mechanisms of YM155 [5,11-15]. We recently confirmed that YM155 exerts its anti-neuroblastoma effects predominantly through survivin suppression [7]. YM155-induced survivin suppression proceeded DNA damage formation. Moreover, YM155 mimicked the effects of RNAi-mediated survivin depletion, whereas Mcl-1 depletion did not affect neuroblastoma cell viability [7]. Furthermore, YM155-adapted UKF-NB-3 neuroblastoma cells had developed resistance to RNAi-mediated survivin depletion [7]. We also investigated the effects of YM155 in neuroblastoma cells with acquired resistance to cisplatin, doxorubicin, or vincristine and detected in concert with previous findings reduced SLC35F2 (mediates cellular YM155 uptake) and increased ABCB1 (causes YM155 efflux) expression as drug-specific resistance mechanisms [3,7,16,17]. Our data further demonstrated that RNAi-mediated p53 depletion mediated resistance to YM155 and survivin depletion suggesting loss of p53 function to be a target-specific resistance mechanism that will affect all approaches that target survivin in neuroblastoma [7].

3

Here, we investigated the effects of YM155 in a larger panel of 101 neuroblastoma cell lines that focused on acquired drug resistance containing 82 drug-adapted neuroblastoma cell lines, which reflected resistance to 15 anti-cancer drugs.

4

Materials and methods

Drugs

YM155 (Sepantronium Bromide) and zosuquidar were purchased from Selleck Chemicals via BIOZOL Diagnostica GmbH (Eching, Germany), verapamil from Sigma-Aldrich (Munich, Germany).

Cells

The MYCN-amplified neuroblastoma cell lines UKF-NB-2, UKF-NB-3, UKF- and UKF-NB-6 were established from stage 4 neuroblastoma patients [18-20]. UKF-NB-3clone1 and UKF-NB-3clone3 are p53 wild-type single cell-derived sub-lines of UKF-NB-3 [20]. Be(2)C, IMR-32, SH-SY5Y, SK-N-AS, and SK-N-SH were obtained from ATCC (Manassas, VA, USA), CHP-134, LAN-6, NGP, and NMB from DMSZ (Braunschweig, Germany), and GI-ME-N from ICLC (Genova, Italy). IMR-5, NLF, and SHEP were kindly provided by Dr Angelika Eggert (Universität Duisburg-Essen, Germany). The NB-S-124 cell line was established by Dr Frank Westermann (DKFZ, Heidelberg, Germany). A master cell bank was established at the beginning of the project, and experiments on cell lines were performed within 20 passages.

Resistant neuroblastoma cell lines were established by continuous exposure to increasing drug concentrations as previously described [20] and derived from the Resistant Cancer Cell Line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html).

All cells were propagated in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% foetal calf serum (FCS), 100IU/ml penicillin and 100µg/ml streptomycin at 37°C. Cells were routinely tested for mycoplasma contamination and authenticated by short tandem repeat profiling.

5

p53-depleted and ABCB1-transduced neuroblastoma cells were established as described previously [20] using the Lentiviral Gene Ontology (LeGO) vector technology (www.lentigo-vectors.de). SH-EP-*MYCN* (TET21N) were cultured and induced as previously described [21].

Viability assay

Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay as described previously [20] or by CellTiterGlo assay (Promega, Walldorf, Germany) following the manufacturer's instructions after 120h incubation.

Western blot

Cells were lysed using Triton-X-100 sample buffer, and proteins were separated by SDS-PAGE. Detection occurred by using specific antibodies against β-actin (Biovision through BioCat GmbH, Heidelberg Germany), ABCB1, poly (ADP-ribose) polymerase (PARP) (both from Cell Signaling via New England Biolabs, Frankfurt, Germany), MYCN (abcam, Cambridge, UK), and survivin (R&D Systems, Minneapolis, MN, USA). Protein bands were visualised by laser-induced fluorescence using infrared scanner for protein quantification (Odyssey, Li-Cor Biosciences, Lincoln, NE, USA).

RNA interference (RNAi)

Transient depletion of ABCB1 was achieved using synthetic siRNA oligonucleotides (ON-TARGETplus SMARTpool) from Dharmacon (Lafayette, CO; USA). Non targeting siRNA (ON-TARGETplus SMARTpool) was used as negative control. Cells were transfected by electroporation using the NEON Transfection System (Invitrogen, Darmstadt; Germany) according to the manufacturer protocol. Cells were grown to 60-80 % confluence, trypsinised, and 1.2×10^6 cells were re-

suspended in 200 µl resuspension buffer R including 2.5 µM siRNA. The electroporation was performed using two 20 millisecond pulses of 1400 V. Subsequently, the cells were transferred into cell culture plates or flasks, containing pre-warmed cell culture medium.

TP53 sequencing

TP53 gene sequencing on cDNAs was performed using the following four pairs of primers: TP53 Ex2-3-f GTGACACGCTTCCCTGGAT and TP53 Ex2-3-r TCATCTGGACCTGGGTCTTC; TP53 Ex4-5-f CCCTTCCCAGAAAACCTACC and TP53 Ex4-5-r CTCCGTCATGTGCTGTGACT; TP53 EX6-7f GTGCAGCTGTGGGTTGATT and TP53 Ex6-7r GGTGGTACAGTCAGAGCCAAC; Tp53 Ex8-9-f CCTCACCATCATCACACTGG and TP53 Ex8-9-r GTCTGGTCCTGAAGGGTGAA. In addition all cell lines were examined for TP53 mutations by sequence analysis of genomic DNA as described previously [20]. PCR was performed as described before [20]. Each amplicon was sequenced bidirectionally.

Statistics

Results are expressed as mean ± S.D. of at least three experiments. Comparisons between two groups were performed using Student's t-test. Three and more groups were compared by ANOVA followed by the Student-Newman-Keuls test. P values lower than 0.05 were considered significant.

Results

Effects of YM155 on the viability of parental neuroblastoma cell lines

YM155 was initially tested in a panel of 86 neuroblastoma cell lines consisting of 17 parental neuroblastoma cell lines and 69 drug-adapted sub-lines (Table S1). The IC_{50} values in the parental cell lines ranged from 0.49nM (UKF-NB-3) to 248nM (LAN-6) (Figure 1, Table S1). All parental cell lines despite from LAN-6, NB-S-124 (77nM), and SK-N-SH (75nM) had IC_{50} values in the range of clinical achievable YM155 plasma concentrations (Figure 1A, Table S1) that were reported to reach up to 56nM [22-24].

ABCB1-expressing neuroblastoma cell lines display low sensitivity to YM155

In concert with previous studies [3,7], ABCB1-expressing neuroblastoma cells displayed relatively low YM155 sensitivity and were (in contrast to low ABCB1-expressing cells) sensitised to YM155 by verapamil and zosuquidar (Figure 1B), two structurally unrelated ABCB1 inhibitors [25].

MYCN status does not influence neuroblastoma cell sensitivity to YM155

MYCN amplification is a major determinant of poor disease outcome in neuroblastoma [8,9]. The YM155 IC_{50} ranged from 0.49nM (UKF-NB-3) to 77nM (NB-S-124) in MYCN-amplified cells and from 3.55nM (SK-N-AS) to 248nM (LAN-6) in not MYCN-amplified cells (Table S2). To exclude the effects of ABCB1, we compared the YM155 IC_{50} in cells with known MYCN status in the presence of the ABCB1 inhibitors verapamil and zosuquidar. In the presence of ABCB1 inhibitors, MYCN-amplified and non-MYC-amplified displayed a similar range of YM155 IC_{50}s (Figure 2A, Table S2). SH-EP-*MYCN* (TET21N) cells express a tetracycline-controllable MYCN transgene. They display low MYCN levels in the presence of tetracycline antibiotics and high MYCN levels in the absence of tetracycline antibiotics [21]. SH-EP-*MYCN* (TET21N)

8

cells displayed similar YM155 IC_{50} values in the absence or presence of doxycycline (Figure 2B, Figure S1).

TP53 status does not predict neuroblastoma cell sensitivity to YM155

Previously, RNAi-mediated p53 depletion was shown to reduce the YM155 sensitivity of the neuroblastoma cell lines UKF-NB-3 and UKF-NB-6 [7]. However, the p53-null SK-N-AS cells displayed an YM155 IC_{50} of 3.55nM that was further reduced to 1.01nM and 1.31nM by verapamil and zosuquidar, respectively (Figure 1, Table S2). Hence, SK-N-AS belongs in the presence of ABCB1 inhibitors to the most YM155-sensitive neuroblastoma cell lines in the panel, despite the lack of functional p53.

To further investigate the relevance of the *TP53* status for the neuroblastoma cell sensitivity to YM155, we determined YM155 IC_{50} values in a panel of 14 nutlin-3-adapted *TP53*-mutant neuroblastoma cell lines [20,26]. Our initial cell line panel included one nutlin-3-adapted neuroblastoma cell line (UKF-NB-3^{r}Nutlin$^{10\mu M}$) that harbours a G245C loss-of-function *TP53* mutation [20] and displayed 2.4-fold reduced YM155 sensitivity relative to the parental UKF-NB-3 cells (Table S1). In addition, we tested YM155 in nutlin-3-resistant, *TP53* mutant sub-lines of two clonal p53 wild-type UKF-NB-3 sub-lines (UKF-NB-3clone1, UKF-NB-3clone3) and the *TP53* wild-type neuroblastoma cell line UKF-NB-6 (Figure 3, Table S3). Only four out of the 14 nutlin-3-resistant neuroblastoma cell lines displayed a >2-fold change in the YM155 IC_{50} relative to the respective parental cells, with 3.3 (UKF-NB-3clone1^{r}Nutlin$^{10\mu M}$I) being the highest fold change (Figure 3, Table S3). These findings do not suggest the cellular *TP53* status to be a good predictor of neuroblastoma cell sensitivity to YM155.

Effects of YM155 on the viability of neuroblastoma cell lines with acquired drug resistance

In a panel of 69 sub-lines of the neuroblastoma cell lines IMR-5, IMR-32, NGP, NLF, SHEP, UKF-NB-2, UKF-NB-3, and UKF-NB-6 with acquired resistance to drug classes including platinum drugs, vinca alkaloids, taxanes, alkylating agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and nucleoside analogues (Table S1), resistance was commonly associated with decreased YM155 sensitivity. However, 48 resistant cell lines displayed YM155 IC_{50} values in the range of therapeutic plasma levels (up to 56nM) (Table S1).

41 (60%) of the resistant cell lines displayed cross-resistance to YM155 (YM155 IC_{50} resistant sub-line/ YM155 IC_{50} respective parental cell line >2). 12 of these cell lines showed a fold change YM155 IC_{50} resistant sub-line/ YM155 IC_{50} respective parental cell line of >2 and <10, 18 (26%) cell lines a fold change >10 and <100, and 11 (16%) cell lines a fold change >100. 20 (29%) resistant cell lines were similarly sensitive to YM155 like the respective parental cell lines (fold change <2 and >0.5). 7 (10%) resistant cell lines were more sensitive to YM155 than the respective parental cell lines (fold change <0.5) (Table S1). There were cell line-specific differences. For example, 8 out of 9 (89%) UKF-NB-3 sub-lines and 9 out of 10 (90%) UKF-NB-6 sub-lines, but only 2 out of 11 NLF sub-lines (18%) displayed cross-resistance to YM155 (Table S1).

The YM155 IC_{50} values in the drug-resistant cell lines ranged from 0.40nM (UKF-NB-3[r]GEMCI[10]) to 21,549nM (IMR-5[r]DOCE[20]) (Table S1). The mean YM155 IC_{50} values for the cell lines with resistance to different drug classes are presented in Figure 4A and Table S4. The IC_{50} values for IMR-5[r]DOCE[20] (21,549nM) and UKF-NB-3[r]DOX[20] (15,700nM) were removed from Figure 4A because we considered them as

outliers that if included would not provide a proper representation of the overall data. They are presented in Figure 4B, Table S1, and Table S4.

The groups also differed in the fraction of cell lines that displayed YM155 IC_{50} values <56nM. All of the 8 parental, 4 alkylating agent-resistant, 5 topoisomerase I inhibitor-resistant, and 6 nucleoside analogue (gemcitabine)-resistant cell lines displayed YM155 IC_{50} values <56nM. Only 15 out of 20 (75%) platinum drug-adapted, 9 out of 14 (64%) topoisomerase II inhibitor-adapted, 5 out of 12 (42%) vinca alkaloid-adapted, and 2 out of 6 (33%) taxane (docetaxel)-adapted cell lines exhibited YM155 IC_{50} values <56nM (Figure 4B, Table S1).

For the topoisomerase II inhibitor (doxorubicin, etoposide)- and platinum drug (carboplatin, cisplatin, oxaliplatin)-adapted cell lines, we had sufficient data to perform drug-specific analyses. For six cell lines, we had doxorubicin- and etoposide-resistant sub-lines (Figure 5A, Figure 5B, Table S1). To determine the mean YM155 IC_{50} value, we again removed the UKF-NB-3 sub-lines because of the high value of UKF-NB-3^{r}DOX[20]. Results revealed that acquired doxorubicin resistance resulted in a generally more pronounced YM155 resistance phenotype than acquired etoposide resistance (Figure 5A, Figure 5B, Table S1).

In addition, the project cell line panel included carboplatin-, cisplatin-, and oxaliplatin-resistant sub-lines of five neuroblastoma cell lines (Figure 5C, Figure 5D, Table S1). Cisplatin and oxaliplatin resistance were associated with a lower degree of YM155 resistance than carboplatin resistance (Figure 5C, Figure 5D, Table S1).

Role of ABCB1 in the YM155 response of drug-adapted neuroblastoma cells

A significant amount of drug-adapted neuroblastoma cell lines displays increased ABCB1 activity [27], and ABCB1 has been previously shown to mediate YM155 resistance [3,7,16]. In agreement with previous results, transduction of

11

neuroblastoma cells with ABCB1 resulted in YM155 resistance, which was reduced by siRNA-mediated ABCB1 depletion (Figure S2). Further, YM155 100nM, a concentration that did not induce survivin depletion in ABCB1-transduced UKF-NB-3 (UKF-NB-3^{ABCB1}) cells after 24h of incubation, reduced cellular survivin levels in UKF-NB-3^{ABCB1} cells in the presence of the ABCB1 inhibitors verapamil and zosuquidar (Figure S2).

Hence, we further examined the effects of verapamil and zosuquidar on YM155 sensitivity in a panel of 60 drug-adapted neuroblastoma cell lines (Table S5). 15 of the drug-adapted cell lines displayed an IC$_{50}$ higher than 56nM. In the presence of verapamil, only six of the drug-adapted cell lines displayed an IC$_{50}$ higher 56nM. In the presence of zosuquidar, only five of the drug-adapted cell lines displayed an IC$_{50}$ higher than 56nM. The YM155 IC$_{50}$s of eight cell lines (IMR-5^{r}DOX[20], IMR-5^{r}VCR[10], IMR^{r}VINB[20], NGP^{r}DOX[20], NGP^{r}ETO[400], UKF-NB-3^{r}CARBO[2000], UKF-NB-3^{r}CDDP[1000], UKF-NB-3^{r}VINOR[40]) were reduced to levels below 56nM by verapamil and zosuquidar. Notably, the fold sensitisation by ABCB1 inhibitors was low (verapamil: 1.2-fold, zosuquidar: 1.5-fold) in NGP^{r}ETO[400], although the YM155 IC$_{50}$s were reduced below 56nM. This suggests that ABCB1 expression is not a dominant YM155 resistance mechanism in NGP^{r}ETO[400] cells (Table S5).

IMR-5^{r}DOCE[20], NGP^{r}VCR[20], and UKF-NB-2^{r}CARBO[2000] were sensitised by verapamil and zosuquidar to YM155. However, the effects of zosuquidar were more pronounced resulting in YM155 IC$_{50}$ values below 56nM, whereas the YM155 IC$_{50}$ values remained above 56nM in the presence of verapamil (Table S5). In NLF^{r}DOX[40] and NLF^{r}VINB[10] cells, zosuquidar (but not verapamil) increased the YM155 IC$_{50}$ values by mechanisms that appear to be unrelated to ABCB1 (Table S5).

12

We selected two parental cell line/ drug-adapted subline pairs (IMR-5/ IMR-5[r]DOCE[20], IMR-32/ IMR-32[r]DOX[20]) for additional confirmatory experiments. The YM155 IC_{50}s in these four cell lines in the absence and presence of zosuquidar determined MTT (used in the screen, measures oxidative phosphorylation in the mitochondria) were very similar to those determined by CellTiterGlo (alternative viability assay that measures ATP production) (Table S6). Both drug-adapted sublines displayed increased ABCB1 levels (Figure S3). Moreover, YM155 500nM, a concentration that did not affect cellular survivin levels and PARP cleavage in IMR-5[r]DOCE[20] cells after 24h incubation, caused survivin depletion and PARP cleavage in IMR-5[r]DOCE[20] cells in the presence of the ABCB1 inhibitors verapamil and zosuquidar (Figure S3).

YM155 is an ABCC1 substrate

NLF[r]VCR[10] cells were sensitised by verapamil but not by zosuquidar to YM155 (Table S5). NLF[r]VCR[10] cells are characterised by ABCC1 (also known as MRP1) expression but do not express ABCB1 [28]. Since only verapamil but not zosuquidar inhibits ABCC1 [29,30], this suggests that ABCC1 also mediates resistance to YM155. In agreement, the ABCC1 inhibitor MK571 substantially reduced YM155 sensitivity in ABCC1-expressing NLF[r]VCR[10] cells but not in the parental NLF cell line that does not express ABCC1 (Table S7).

Cross resistance to YM155 is caused by multiple resistance mechanisms in drug-adapted neuroblastoma cells

Although our data indicate that ABCB1 plays an important role in the cross-resistance of drug-adapted neuroblastoma cell lines to YM155, additional mechanisms are also involved. Of the 60 drug-adapted cell lines, 35 displayed cross-resistance to

13

YM155 (fold change YM155 IC_{50} resistant sub-line/ YM155 IC_{50} respective parental cell line >2). In 24 of these drug-adapted cell lines, the YM155 IC_{50} remained >2-fold higher in the presence of verapamil compared to the YM155 IC_{50} of the respective parental cell line in the presence of verapamil (Table S5). Similarly, in 19 drug-adapted cell lines, the YM155 IC_{50} remained >2-fold higher in the presence of zosuquidar compared to the YM155 IC_{50} of the respective parental cell line in the presence of zosuquidar (Table S5). This included cell lines that were not sensitised by verapamil and/ or zosuquidar to YM155 and those that were sensitised to YM155 by verapamil and/ or zosuquidar but not to the level of the parental cells (Table S5).

Discrepancies in the effects of the ABCB1 inhibitors verapamil and zosuquidar on neuroblastoma cell sensitivity to YM155

Both, verapamil and zosuquidar, sensitised 25 of the drug-adapted cell lines to YM155 by >2-fold. There was an overlap of 23 cell lines that were sensitised to YM155 by both ABCB1 inhibitors by >2-fold (Table S5). Among the exceptions was the ABCC1-expressing cell line NLF[r]VCR[10] that has already been described above. NGP[r]GEMCI[20] cells were sensitised to YM155 by zosuquidar, whereas verapamil slightly increased the YM155 IC_{50} value in this cell line. In addition, UKF-NB-3[r]TOPO[20] cells were sensitised to YM155 by verapamil by >2-fold (fold change 3.7) but not by zosuquidar (fold change 1.4). UKF-NB-6[r]CARBO[2000] cells were sensitised by zosuquidar to YM155 by >2-fold (fold change 2.3) but not by verapamil (fold change 1.3) (Table S5). The reasons for these differences remain unclear.

Since we had detected differences between the effects of the ABCB1 inhibitors verapamil and zosuquidar on the YM155 IC_{50} values in a number of cell lines, we compared both drugs in a wider panel of 74 cell lines (Figure 6, Table S5). In 45 cell lines, the YM155 IC_{50} values were in a similar range in the presence of verapamil and

14

zosuquidar (YM155 IC_{50} in the presence of verapamil/ YM155 IC_{50} in the presence of zosuquidar >0.5 and <2.0). This included 33 cell lines that were neither sensitised to YM155 by verapamil nor by zosuquidar and 12 cell lines that were sensitised by verapamil and zosuquidar by more than 2-fold and in a similar fashion (Table S5).

13 cell lines were more strongly sensitised to YM155 by verapamil than by zosuquidar (YM155 IC_{50} in the presence of verapamil/ YM155 IC_{50} in the presence of zosuquidar <0.5). Only one of these cell lines (UKF-NB-6[r]ETO[200]) was sensitised by both verapamil and zosuquidar to YM155 by more than 2-fold. The remaining cell lines were either only sensitised to YM155 by more than 2-fold by verapamil and not by zosuquidar, or zosuquidar increased the YM155 IC_{50} by mechanisms that do not appear to be associated with effects on ABCB1 (Table S5).

16 cell lines were more strongly sensitised to YM155 by zosuquidar than by verapamil (YM155 IC_{50} in the presence of verapamil/ YM155 IC_{50} in the presence of zosuquidar >2.0). NGP[r]GEMCI[20] cells were only sensitised by zosuquidar to YM155 but not by verapamil. The other 15 of these cell lines were sensitised by more than 2-fold to YM155 by both compounds with zosuquidar exerting more pronounced effects. The relative differences between these two drugs on the YM155 sensitivity of these cell lines ranged from 2.2 (NLF[r]DOCE[20], UKF-NB-3[r]CARBO[2000]) to 65.2 (UKF-NB-3[r]DOCE[10]) (Table S5).

15

Discussion

YM155 has been suggested as therapeutic option for the treatment of neuroblastoma including therapy-refractory disease [3,4,7]. In a larger cell line panel, mainly consisting of neuroblastoma cell lines with acquired drug resistance, we here show that 77 out of 101 tested neuroblastoma cell lines displayed YM155 IC_{50} values in the range of clinically achievable plasma concentrations up to 56 nM [22-24].

Although MYCN amplification is a major indicator of poor prognosis in neuroblastoma [8,9], the efficacy of YM155 was independent of the MYCN status. As previously shown [3,7,16], ABCB1-expressing cells displayed low YM155 sensitivity and were sensitised by the ABCB1 inhibitors verapamil and zosuquidar to YM155. The role of ABCB1 expression in neuroblastoma is not clear. ABCB1 expression at diagnosis is commonly regarded not to be of prognostic relevance [31], although ABCB1 expression has been reported in a significant fraction of patients [3,32,33]. Notably, six (35%) out of the 17 parental neuroblastoma cell lines investigated in this study (Be(2)C, LAN-6, NB-S-124, SHEP, SK-N-AS, SK-N-SH) are characterised by ABCB1 activity, which is similar to a previous study, although there was some overlap between the cell line panels [3]. Limited information is available on ABCB1 expression as acquired drug resistance mechanism in neuroblastoma. Many drug-adapted neuroblastoma cell lines display enhanced ABCB1 activity [26,34], and drug-adapted cell lines have been shown to reflect clinically relevant resistance mechanisms [20,35-44]. Some clinical hints may also point towards a role of ABCB1 in acquired resistance in neuroblastoma [33,45]. Hence, ABCB1 may represent an acquired resistance mechanism in neuroblastoma.

In contrast to ABCB1, ABCC1 (also known as MRP1) is generally accepted as prognostic factor in neuroblastoma [24]. Interestingly, NLF[r]VCR[10] cells (that express

16

ABCC1 but not ABCB1 [28]) were sensitised to YM155 by verapamil (inhibits ABCB1 and ABCC1 [29]) but not by zosuquidar (inhibits only ABCB1 [30]). This suggests that ABCC1 mediates YM155 resistance.

Verapamil and zosuquidar further differed in their effects on neuroblastoma cell sensitivity to YM155. Zosuquidar protected some ABCB1-negative cell lines from YM155-induced toxicity by unknown mechanisms. More strikingly, we identified cell line-specific differences in the relative potencies of verapamil and zosuquidar on YM155 activity. Twelve ABCB1-expressing cell lines were similarly sensitised to YM155 by verapamil and zosuquidar. Few cell lines were stronger sensitised by verapamil than by zosuquidar. These data are difficult to interpret with regard to ABCB1 because verapamil interacts with a broader range of transporters than the specific ABCB1 inhibitor zosuquidar [29,30,46]. However, 15 cell lines were sensitised by more than 2-fold to YM155 by verapamil and zosuquidar with zosuquidar exerting up to 65-fold (UKF-NB-3^{r}DOCE^{10}) more pronounced effects than verapamil. Hence, the relative effects of verapamil and zosuquidar on ABCB1-mediated YM155 transport differ in individual cell lines from similar efficacy (in 12 cell lines) to 65-fold increased zosuquidar efficacy over verapamil. Since zosuquidar is regarded as highly specific ABCB1 inhibitor [30,46], this difference seems to depend on discrepancies in the interaction with ABCB1. Notably, ABCB1 polymorphisms and mutations may substantially alter ABCB1 substrate specificity [47,48], which may explain the cell line-specific variation in the relative influence of zosuquidar and verapamil on ABCB1 function. Hence, it might be possible to design ABCB1 inhibitors that preferentially target specific ABCB1 variants. In this context, we have previously shown that certain ABCB1 inhibitors preferentially interfere with the ABCB1-mediated transport of certain ABCB1 substrates [49].

17

Although RNAi-mediated p53 depletion decreases neuroblastoma cell sensitivity to YM155 as previously demonstrated [7], only 4 out of 14 nutlin-3-adapted *TP53*-mutant neuroblastoma cell lines displayed a >2-fold increased YM155 IC_{50} relative to the respective parental cell line. All nutlin-3-resistant cell lines remained sensitive to low nanomolar YM155 concentrations with IC_{50} values ranging from 0.40 to 1.50nM. This shows that the role of p53 depends on the individual cellular context and that the *TP53* status on its own does not indicate neuroblastoma cell sensitivity to YM155. These data are in accordance with initial findings that reported the activity of YM155 to be unrelated to the *TP53* status [10,50].

The adaptation of neuroblastoma cell lines to drugs from different classes was associated with varying YM155 sensitivity profiles. Neuroblastoma cell adaptation to topoisomerase I inhibitors, the nucleoside analogue gemcitabine, or alkylating agents was not associated with a pronounced YM155 resistance phenotype. In contrast, neuroblastoma cell lines adapted to the taxane docetaxel or vinca alkaloids exhibited distinct cross-resistance to YM155. Topoisomerase II inhibitors and platinum drugs displayed intermediate potential to induce YM155 resistance.

For the topoisomerase II inhibitor- and platinum drug-adapted neuroblastoma cell lines, we could perform drug-specific sub-analyses. Among the topoisomerase II inhibitors, doxorubicin-resistant cells were more likely to be YM155-resistant than etoposide-resistant cells. This result may not be too surprising. Although doxorubicin and etoposide both inhibit the religation of the topoisomerase II cleavage complexes, they are structurally different compounds that differ in their exact interaction with this target and may exert additional varying effects [51-53]. Perhaps more strikingly, we also found differences among the carboplatin-, cisplatin-, and oxaliplatin-resistant cell lines. Carboplatin-resistant cells were more frequently YM155-resistant than cisplatin-

18

or oxaliplatin-resistant cells. This is surprising because platinum drugs share a similar mechanism of action. In particular, the effects of carboplatin and cisplatin are thought to be much more related to each other than to oxaliplatin [54,55]. The underlying reasons remain unclear, but the findings indicate substantial gaps in our understanding of the action of these frequently used drugs that need to be filled.

In conclusion, the investigation of YM155 in 101 neuroblastoma cell lines revealed complex sensitivity profiles and that larger panels of model systems are needed to uncover this complexity. Our findings confirm 1) that YM155 is a drug candidate for neuroblastoma including therapy-refractory disease with the majority of cell lines being sensitive to clinically achievable YM155 concentrations and 2) that ABCB1 is an important determinant of YM155 sensitivity. Notably, there were substantial differences in the relative efficacy of the ABCB1 inhibitors verapamil and zosuquidar in sensitising ABCB1-expressing cells to YM155. These differences may be caused by sequence variations in the transporters in the different cell lines, which suggests that it may be possible to design variant-specific ABCB1 inhibitors. Moreover, we present novel findings indicating 1) that YM155 resistance is also mediated by ABCC1 (an ABC transporter of prognostic relevance in neuroblastoma [31]), 2) that (in contrast to previous assumptions) the p53 status does not indicate YM155 sensitivity, and 3) that YM155 cross-resistance profiles differ between cell lines adapted to drugs from different classes and even between cell lines adapted to drugs as similar as cisplatin and carboplatin. YM155 has shown moderate effects in clinical trials so far [24,56,57]. An improved understanding of the complex processes underlying response to this drug may enable the identification of biomarkers and the design more effective personalised therapies.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgement

References

1. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett. 2005;228:133-41.

2. Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer. 2011;18:657-68.

3. Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer. 2012;48:763-71.

4. Liang H, Zhang L, Xu R, Ju XL. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci. 2013;17:2909-15.

5. Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, et al. Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta. 2014 Apr;1845(2):202-20.

6. Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ. BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma. Oncogene. 2016;35:2052-61.

7. Voges Y, Michaelis M, Rothweiler F, Schaller T, Schneider C, Politt K, et al. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell Death Dis. 2016;7:e2410.

8. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35:337-47.

21

9. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985-93.

10. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67:8014-11.

11. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012;70:207-12.

12. Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, et al. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015;8:39.

13. Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol. 2011;82:1066-72.

14. Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, et al. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget. 2014;5:10237-50.

15. de Necochea-Campion R, Diaz Osterman CJ, Hsu HW, Fan J, Mirshahidi S, Wall NR, et al. AML sensitivity to YM155 is modulated through AKT and Mcl-1. Cancer Lett. 2015;366:44-51.

16. Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab Dispos. 2011;39:2314-20.

17. Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014;10:768-73.

18. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer. 2003;104:36-43.

19. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, et al. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol. 2005;27:1029-37.

20. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2:e243.

21. Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13:803-12.

22. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26:5198-203.

23. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3872-80.

24. Aoyama Y, Kaibara A, Takada A, Nishimura T, Katashima M, Sawamoto T. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma. Invest New Drugs. 2013;31:443-51.

25. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 2007;113:429-41.

26. Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, et al. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis. 2012;3:e294.

27. Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, et al. Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs. Transl Oncol. 2013;6:685-96.

28. Löschmann N, Michaelis M, Rothweiler F, Voges Y, Balónová B, Blight BA, et al. ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance. Oncotarget. 2016;7:58051-64.

29. Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer. 1995;72:418-23.

30. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290:854-62.

31. Yu DM, Huynh T, Truong AM, Haber M, Norris MD. ABC transporters and neuroblastoma. Adv Cancer Res. 2015;125:139-70.

32. Pituch-Noworolska A, Zaremba M, Wieczorek A. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol. 2009;60:168-73.

33. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M. Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Surg. 2009;44:377-80.

34. Michaelis M, Rothweiler F, Löschmann N, Sharifi M, Ghafourian T, Cinatl J Jr. Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status. Oncotarget. 2015;6:17605-20.

35. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43.

36. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7.

37. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387-90.

38. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22:373-88.

39. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020-9.

40. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3:1030-43.

41. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346:1480-6.

42. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.

43. Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, et al. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun. 2016;7:12609.

44. Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23:250-5.

45. Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, Philippé, Laureys GG. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer. 1997;80:1250-7.

46. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19:1946-2025.

47. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010;44:152-67.

48. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012;27:85-105.

49. Michaelis M, Rothweiler F, Wurglics M, Aniceto N, Dittrich M, Zettl H, et al. Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport. Oncotarget. 2016;7:11664-76.

50. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011;102:614-21.

51. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421-33.

52. Meresse P, Dechaux E, Monneret C, Bertounesque E. Etoposide: discovery and medicinal chemistry. Curr Med Chem. 2004;11:2443-66.

53. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 2009;12:114-26.

54. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-84.

55. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103-24.

56. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27:4481-6.

57. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012;23:968-73.

Figure legends

Figure 1. Anti-neuroblastoma effects of YM155 in a panel of 17 neuroblastoma cell lines. A) YM155 concentrations that reduce the viability of neuroblastoma cell lines by 50% (IC_{50}) as determined by MTT assay after a 5-day treatment period. Numerical values are presented in Table S1. B) Effects of the ABCB1 inhibitors verapamil (5 µM) and zosuquidar (1.25 µM) on the YM155 IC_{50} values in neuroblastoma cell lines characterised by high or low ABCB1 levels displayed as fold change YM155 IC_{50}/ YM155 IC_{50} in the presence of ABCB1 inhibitor. Numerical data and the effects of the ABCB1 inhibitors alone on cell viability are presented in Table S5.

Figure 2. Effects of YM155 on the viability of neuroblastoma cells in dependence on the MYCN status. A) YM155 concentrations that reduce the viability of neuroblastoma cell lines by 50% (IC_{50}) were determined by MTT assay after a 5-day treatment period in the presence of the ABCB1 inhibitors verapamil (5 µM) or zosuquidar (1.25 µM) to avoid interference of ABCB1-mediated effects with MYCN-mediated effects. Numerical data are presented in Table S2. B) YM155 IC_{50} values in SH-EP-*MYCN* (TET21N) cells in the absence or presence of doxycycline as determined by MTT assay after a 120h of treatment.

Figure 3. Effects of YM155 on the viability of parental p53 wild-type neuroblastoma cell lines and their p53 mutant nutlin-3-adapted sub-lines. YM155 concentrations that reduce neuroblastoma cell viability by 50% (IC_{50}) as determined by MTT assay after a 5-day treatment period. Numerical data are presented in Table S3.

29

Figure 4. Effects of YM155 on the viability of neuroblastoma cell lines adapted to particular drug classes. A) YM155 concentrations that reduce neuroblastoma cell viability by 50% (IC_{50}) as determined by MTT assay after a 5-day treatment period. Values are presented as mean values over all cell lines from the individual groups. There were no statistically significant differences. The cell lines UKF-NB-3[r]DOX[20] and IMR-5[r]DOCE[20] were not included into this analysis because they were regarded as outliers (please refer to the text). Numerical data are presented in Table S4. B) Distribution of the YM155 IC_{50} values within the groups of drug-adapted cancer cell lines. Numerical data are presented in Table S1. [1]UKF-NB-3[r]DOX[20] (YM155 IC_{50} 15,700 $\pm$ 1,019 nM); [2]IMR-5[r]DOCE[20] (YM155 IC_{50} 21,549 $\pm$ 638 nM); [3]UKF-NB-2[r]DOX[20] (YM155 IC_{50} 1,108 $\pm$ 179 nM); [4]NGP[r]VCR[20] (YM155 IC_{50} 6,986 $\pm$ 716 nM); [5]UKF-NB-2[r]VCR[10] (YM155 IC_{50} 5,940 $\pm$ 247 nM); [6]IMR-5[r]VINOR[20] (YM155 IC_{50} 4,978 $\pm$ 147 nM); [7]IMR-5[r]VINB[20] (YM155 IC_{50} 1,608 $\pm$ 212 nM)

Figure 5. Effects of YM155 on the viability of neuroblastoma cell lines adapted to particular drugs. A) YM155 concentrations that reduce the viability of neuroblastoma cell lines adapted to the topoisomerase II inhibitors doxorubicin or etoposide by 50% (IC_{50}) as determined by MTT assay after a 5-day treatment period. Values are presented as mean values over all cell lines from the individual groups. The cell line UKF-NB-3[r]DOX[20] was not included into this analysis because it was regarded as outliers (please refer to the text). B) Distribution of the YM155 IC_{50} values in doxorubicin- and etoposide-adapted cells. C) YM155 concentrations that reduce the viability of neuroblastoma cell lines adapted to the platinum drugs carboplatin, cisplatin, or oxaliplatin by 50% (IC_{50}) as determined by MTT assay after a 5-day treatment

30

period. D) Distribution of the YM155 IC_{50} values in carboplatin-, cisplatin- and oxaliplatin-adapted cells. Numerical data are presented in Table S1 and Table S4. [1]UKF-NB-3[r]DOX[20] (YM155 IC_{50} 15,700 $\pm$ 1,019 nM)

Figure 6. Comparison of verapamil- and zosuquidar-induced neuroblastoma cell sensitisation to YM155 in a panel of 74 neuroblastoma cell lines. The fold sensitisation (YM155 IC_{50}/ YM155 IC_{50} in the presence of ABCB1 inhibitor) was determined by MTT assay after neuroblastoma cell incubation with YM155 for 120 h in the absence or presence of verapamil (5 μM) or zosuquidar (1.25 μM). Numerical data are presented in Table 5. [1]UKF-NB-3[r]DOX[20], fold change 9235; [2]IMR-5[r]DOCE[20], fold change 1581; [3] UKF-NB-3[r]DOCE[10], fold change 939.

Figure 1

A

YM155 IC$_{50}$ (nM)

B

fold sensitisation (YM155 IC$_{50}$ / YM155 IC$_{50}$ in the presence of an ABCB1 inhibitor)

Figure 2

A

YM155 IC$_{50}$ (nM) in the presence of ABCB1 inhibitors

YM155 IC$_{50}$ (nM) in the presence of ABCB1 inhibitors

B

SH-EP-*MYCN* (TET21N)

YM155 IC$_{50}$ (nM)

Figure 3

Figure 4

A

YM155 IC$_{50}$ (nM)

B

YM155 IC$_{50}$ (nM)

Figure 5

Figure 6

verapamil   zosuquidar

$YM155\ IC_{50}/\ YM155\ IC_{50}$ in the presence of an ABCB1 inhibitor